MIRCERA.com

MIRCERA provides targeted haemoglobin (Hb) stability during maintenance therapy with once-monthly dosing in all CKD patients. MIRCERA not only maintains Hb stability that is required for all CKD patients, but once-monthly dosing during the maintenance phase of treatment can also save healthcare professionals and their staff precious time so they can focus on other aspects of patient care. MIRCERA provides a smooth and steady rise in Hb levels which allows clinicians to safely and effectively correct anaemia.

 

This section aims to provide the information required to use MIRCERA, including how to correct Hb levels with MIRCERA, converting patients from shorter-acting erythropoiesis-stimulating agents (ESAs) to MIRCERA whilst maintaining Hb levels, recommended doses of MIRCERA and safety information.